Prenatal multiple micronutrient supplementation in the Parepare district, Indonesia; population characteristics and intake adherence.

BMC Public Health

Department of Pediatrics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Published: March 2025

Background: Micronutrient deficiencies among pregnant women remain highly prevalent in low and middle-income countries. Multiple micronutrient supplementation (MMS) has been proven more beneficial than standard iron-folic acid supplementation in reducing adverse pregnancy outcomes. Limited data on adherence to MMS in pregnant women in programmatic settings is available. Therefore, our study aims to assess adherence to the recommended intake of a multiple micronutrient supplement (UNIMMAP-MMS) in relation to demographic characteristics alongside a community-based MMS program.

Method: A prospective longitudinal study was performed in the Parepare district, South Sulawesi province, Indonesia, including 1216 participants. MMS was provided at the first antenatal care visit and women were followed up until delivery. The number of MMS tablets consumed, the start of MMS intake and information regarding possible intake determinants were recorded. Adherence was defined as ≥ 90 tablets. Binary logistic regression was used to assess associations between characteristics of women and adherence.

Results: Among the 655 women (53.9%) who started MMS intake in the first trimester, approximately 90% continued using MMS in the following trimesters and 75.3% consumed MMS ≥ 90 tablets. Among the 41.2% of women who started in the second trimester, 90% continued intake in the third trimester and 32.3% consumed ≥ 90 tablets. Only 4.9% started MMS in the third trimester. Overall adherence to MMS was 53.9%. Factors that impacted MMS intake were pregnancy interval ≤ 2y (AOR = 0.65, 95% CI 0.46, 0.92), start of MMS use in the second trimester and third trimester (AOR = 0.15, 95% CI 0.12, 0.20) and (AOR = 0.01, 95% CI 0.00, 0.04) respectively, being overweight (AOR = 1.44, 95% CI 1.04, 2.00) and experiencing no side effects (AOR = 3.46, 95% CI 1.82, 6.58).

Conclusion: Implementation of MMS via community health centers resulted in high adherence once supplementation started. As many women started MMS late, attention to antenatal visit planning earlier in pregnancy can be further improved.

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12889-025-22129-0DOI Listing

Publication Analysis

Top Keywords

mms
14
multiple micronutrient
12
mms intake
12
started mms
12
third trimester
12
micronutrient supplementation
8
parepare district
8
pregnant women
8
adherence mms
8
start mms
8

Similar Publications

Background: Micronutrient deficiencies among pregnant women remain highly prevalent in low and middle-income countries. Multiple micronutrient supplementation (MMS) has been proven more beneficial than standard iron-folic acid supplementation in reducing adverse pregnancy outcomes. Limited data on adherence to MMS in pregnant women in programmatic settings is available.

View Article and Find Full Text PDF

Here, we demonstrate through AFM imaging and CD spectroscopy that the binding of silver ions (Ag) to poly(dGdC), a double-stranded (ds) DNA composed of two identical repeating strands, at a stoichiometry of one Ag per GC base pair induces a one-base shift of one strand relative to the other. This results in a ds nucleic acid-Ag conjugate consisting of alternating CC and GG base pairs coordinated by silver ions. The proposed organization of the conjugate is supported by the results of our Quantum Mechanical (QM) and Molecular Mechanics (MMs) calculations.

View Article and Find Full Text PDF

Introduction: Multiple micronutrient deficiencies might increase the adverse outcome during pregnancy and after birth. Considering the WHO recommendations since 2016 and scientific evidence from previous studies that multiple-micronutrient supplementation (MMS) is more effective than iron folic acid (IFA) in improving pregnant women's health, it is imperative to conduct an economic evaluation to assess the cost-effectiveness of MMS compared with IFA.

Methods: We conducted a systematic review from PubMed and Scopus to identify the cost-effectiveness analyses of MMS compared to IFA for pregnant women up to January 2024.

View Article and Find Full Text PDF
Article Synopsis
  • Australia and New Zealand have the highest skin cancer rates globally, particularly in non-metropolitan areas, with Mohs micrographic surgery (MMS) being the preferred treatment for keratinocyte cancers due to its effective cure rates and reduced tissue loss.
  • This study analyzed MMS cases from The Skin Hospital in 2017, comparing tumour and defect sizes between patients from the Sydney Metropolitan Area (SMA) and those from Outside Metropolitan Sydney (OMS), including further breakdown of OMS into Non-Sydney Metropolitan (NSM) and Regional, Rural, and Remote (RRR) groups.
  • Results indicated that OMS patients had larger tumours and defects than SMA patients, suggesting that patients outside major cities face barriers to accessing timely specialized care, highlighting the need
View Article and Find Full Text PDF

Nanoparticle delivery of CD68 siRNA inhibits neuroimmune responses by inhibiting activation of M1 macrophages.

Int Immunopharmacol

March 2025

First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China; Liaoning Provincial Collaborative Innovation Center for Medical Testing and Drug Research, Jinzhou Medical University, Jinzhou, China; Department of Orthopedic, Third Affiliated Hospital of Jinzhou Medical University, Jinzhou, China. Electronic address:

CD68 is a vital costimulatory molecule expressed on macrophages/microglia (M/Ms) and plays a critical role in their activation. By targeting this molecule, therapeutic interventions can potentially prevent the homing of M/Ms. to the lesion site.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!